CVVHDF Significantly Alters Dosing Requirements for Both Polymyxin and Ceftazidime-Avibactam
Yes, continuous venovenous hemodiafiltration (CVVHDF) substantially changes dosing recommendations for both polymyxin and ceftazidime-avibactam (Zavicefta), requiring specific dose adjustments to maintain therapeutic efficacy while avoiding toxicity.
Polymyxin Dosing During CVVHDF
Colistin (Polymyxin E)
For patients on continuous renal replacement therapy (CRRT), maintain a loading dose of 5 mg CBA/kg IV, followed by at least 9 million IU/day as maintenance 1. The standard maintenance formula of 2.5 mg CBA × (1.5 × CrCl + 30) IV q12h does not apply during CVVHDF 2.
Critical point: Do not reduce the colistin dose during CRRT—the loading dose remains essential, and maintenance dosing should be at least 9 million IU/day despite renal replacement 1. This contrasts sharply with intermittent hemodialysis, where 2 million IU every 12 hours is appropriate 1.
Polymyxin B
Polymyxin B dosing does NOT require adjustment during CVVHDF 1. Use the standard dose of 1.5-3 mg/kg/day in 2 divided doses, with a loading dose of 2-2.5 mg/kg 1. This is a major advantage over colistin, as polymyxin B clearance is not significantly affected by renal replacement therapy and may have lower nephrotoxicity 1.
Ceftazidime-Avibactam (Zavicefta) Dosing During CVVHDF
CVVHDF significantly increases clearance of both ceftazidime and avibactam, requiring higher and more frequent dosing than standard regimens 3, 4.
Key Pharmacokinetic Changes
- CVVHDF increases ceftazidime clearance to 2.46 ± 0.29 L/h (vs. 0.9 ± 0.11 L/h without CVVHDF) 3
- Avibactam clearance increases to 2.89 ± 0.41 L/h (vs. 1.09 ± 0.08 L/h without CVVHDF) 3
- CRRT becomes the primary elimination pathway, with extracorporeal clearance accounting for 28.8-60% for ceftazidime and 14-33% for avibactam 5
Dosing Algorithm for CVVHDF
For standard PK/PD targets (100%fT ≥ MIC for ceftazidime + 100%fT ≥ 1.0 mg/L for avibactam):
- MIC ≤ 8 mg/L: Standard dose of 2.5 g IV q8h achieves >90% PTA during CVVHDF 3
- MIC 16-64 mg/L: Requires 3000 mg + 750 mg q8h to achieve adequate PTA 3
For aggressive PK/PD targets (100%fT ≥ 4× MIC + 100%fT ≥ 4.0 mg/L):
- MIC ≤ 2 mg/L: Standard 2.5 g q8h achieves >90% PTA during CVVHDF 3
- MIC 4-16 mg/L: Only 3000 mg + 750 mg q8h achieves adequate PTA 3
- Consider therapeutic drug monitoring (TDM) as no standard regimen consistently meets optimal targets for higher MICs 3
Critical Warnings
- Risk of excessive drug exposure: The standard 2.5 g q8h regimen may cause toxicity—90.48% of CRRT patients showed ceftazidime concentrations exceeding the neurotoxicity threshold of 104 mg/L 4
- CVVH vs. CVVHD differences: CVVH demonstrates higher clearance for both drugs compared to CVVHD, requiring attention to the specific CRRT modality 4
- Microbiologic outcomes: In patients on CVVH, the most commonly used dose was 1.25 g q8h, but microbiologic cure was independently associated with higher daily doses 6
Combination Therapy Considerations
When combining polymyxin with ceftazidime-avibactam during CVVHDF:
- Both drugs require dose optimization based on CRRT parameters
- Polymyxin-based combinations are recommended for CRE bloodstream infections (2D evidence) 2
- Therapeutic drug monitoring is strongly recommended for both agents during CRRT to balance efficacy and toxicity 7, 3
Practical Implementation
- Always use loading doses for both colistin and polymyxin B regardless of CRRT status 1
- Maintain high maintenance doses of colistin (≥9 million IU/day) during CVVHDF 1
- Do not adjust polymyxin B for CVVHDF 1
- For ceftazidime-avibactam: Start with standard 2.5 g q8h but obtain TDM and adjust based on MIC, clinical response, and drug levels 3, 4
- Monitor for neurotoxicity with ceftazidime-avibactam, especially if plasma concentrations exceed 104 mg/L 4
- Consider extended or continuous infusion of beta-lactams when treating high-MIC organisms during CRRT 2